Phase I Dose Escalation Study of Taselisib (GDC-0032), an...

  • Main
  • 2017 / 03
  • Phase I Dose Escalation Study of Taselisib (GDC-0032), an...
Cancer Discovery 2017 / 03

Phase I Dose Escalation Study of Taselisib (GDC-0032), an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors

Juric, Dejan, Krop, Ian, Ramanathan, Ramesh K., Wilson, Timothy R, Ware, Joseph A, Sanabria Bohorquez, Sandra, Savage, Heidi, Sampath, Deepak, Salphati, Laurent, Lin, Ray, Jin, Huan, Parmar, Hema, Hsu
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Cancer Discovery
DOI:
10.1158/2159-8290.CD-16-1080
Date:
March, 2017
File:
PDF, 2.06 MB
english, 2017
Conversion to is in progress
Conversion to is failed